SCHEMBL1507944

SCHEMBL1507944

CC(C)(C)OC(=O)Nc1cccc2ccc(CNCc3ccc4cccc(NC(=O)OC(C)(C)C)c4n3)nc12

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.43
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
MAPT P10636 3/20 0.40
PIM1 P11309 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
PDE10A Q9Y233 3/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
METAP1 P53582 1/20 0.38
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
PDE4D Q08499 1/20 0.38
P2RX7 Q99572 1/20 0.38
GAA P10253 1/20 0.38
KDM4A O75164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507749 0.90 TP53 (0.40) PLAUHDAC1HDAC2MAPTPIM1
SCHEMBL1507701 0.86 PLAU (0.42) PLAUMAPTPIM1PIM2PDE10A
SCHEMBL22765025 0.85 PLAU (0.41) PLAUMAPTPIM1PIM2PDE10A
SCHEMBL30471577 0.82 MAPT (0.57) MAPTTP53THRBGAA
SCHEMBL5959295 0.82 PLAU (0.49) PLAUMAPTRXFP1METAP1TP53
SCHEMBL7748081 0.82 MAPT (0.57) MAPTTP53THRBGAA
SCHEMBL14551175 0.81 PLAU (0.46) PLAUMAPTPIM1PIM2RXFP1
SCHEMBL1507889 0.80 TP53 (0.40) PLAUMAPTPIM1PIM2PDE10A
SCHEMBL22556188 0.78 TDP1 (0.61) MAPTHDAC6METAP1TP53GAA
SCHEMBL14551174 0.75 PLAU (0.43) PLAUMAPTPIM1PIM2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324196-B2 Polyquinoline derivatives and the therapeutic use thereof PALUMED S.A. (FR) 2012-12-04 US claimed
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-11-01 US claimed
US-8247396-B2 Polyquinoline derivatives and therapeutic use thereof PALUMED S.A. (FR) 2012-08-21 US claimed
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US claimed
US-8324196-B2 Polyquinoline derivatives and the therapeutic use thereof PALUMED S.A. (FR) 2012-12-04 US disclosed
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-11-01 US disclosed
US-8247396-B2 Polyquinoline derivatives and therapeutic use thereof PALUMED S.A. (FR) 2012-08-21 US disclosed
EP-2289891-A2 Novel polyquinoline derivates and the therapeutic use thereof Palumed S.A. (FR) 2011-03-02 EP disclosed
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF HTT, APP, PSEN1 PLAU 3064/4885HDAC1 1808/4885HDAC2 2670/4885
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF HTT, UBQLN2, UBQLN1 PLAU 3086/4885HDAC1 1127/4885HDAC2 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.